The drug Byetta (exenatide), manufactured by Amylin Pharmaceuticals and Bristol Myers Squibb is an injectable drug that has been prescribed to millions of Americans with Type 2 diabetes to lower blood glucose levels. Recent studies have linked Byetta, along with other drugs in the same class of medications, Januvia, Janumet and Victoza to pancreatitis and pancreatic cancer. Acute pancreatitis and pancreatic cancer are very serious conditions that can cause death. A new study by researchers at UCLA linked Byetta, along with other drugs in this incretin mimetic class of drugs to pancreatic damage that can lead to cancer, and the FDA continues to study this information.
Cases are already filed against Amylin, Merck & Company and Novo Nordisk in Federal Court
A multi-district case has been organized in the United States District Court for the Southern District of California for purposes of discovery. These cases were filed against Januvia makers Merck & Company, Byetta’s manufacturer, Amylin, Bristol Myers Squibb, as well as Eli Lilly, a prior pharmaceutical partner with Amylin, and Novo Nordisk, the manufacturer of Victoza. The lawsuits were recently consolidated into a multi-district litigation by the federal judicial panel, and discovery is progressing.
Byetta was designed to help diabetics regulate blood sugar
Byetta (exenatide) is a glucagon like peptide antagonist that impacts the GLP-1 metabolic pathway to help diabetics regulate their blood sugar and A1C. Scientific studies show that Byetta and other incretin mimentic drugs used to treat type 2 diabetes can cause both hemorrhagic and necrotizing pancreatitis. According to a 2011 study in the Journal Gastroenterology, based on a clinical study done at the University of California at Los Angeles (UCLA) people taking Byetta, Januvia, Janumet and Victoza and for type 2 diabetes are significantly more likely to develop pancreatic cancer, while people taking Januvia are also significantly more likely to develop thyroid cancer. Contact our Byetta lawsuit lawyers in Pennsylvania to discuss your case more thoroughly.
JAMA finds people taking Incretin Mimetic Drugs are likely to be hospitalized for pancreatitis
In addition, new research published in the Journal of the American Medical Association (JAMA) showed that patients taking incretin mimetic drugs such as Byetta are significantly more likely to develop pancreatic ailments and be hospitalized for acute pancreatitis, often a precursor to pancreatic cancer
Although this information on development of pancreatic cancer has been available since 2011, Amylin, Merck, Bristol Myers Squibb and Novo Nordisk have been reluctant to warn the public about the increased risk for developing these devastating conditions after taking Byetta, Januvia, Janumet and Victoza. Despite these risks, the FDA recently declined to update the existing warnings on the drugs in their prescribing information.
Schedule a Consultation at Our Williamsport, Pennsylvania, Office
If you suspect Byetta use for more than six months caused pancreatic cancer in you or a loved one, you need legal help so you can seek justice. If you or a loved one has taken Byetta, contact us today to learn about your legal rights and the potential compensation available. Call attorney Cliff Rieders, Esquire, of Rieders, Travis, Humphrey, Waters & Dohrmann, 570-323-8711, to see whether you or a loved one may be entitled to compensation from the harm caused by the drug company.